… This review will focus on gastroesophageal adenocarcinomas (GEA); additional information
on the genomics of esophageal squamous cell carcinomas (ESCC) can be found in ref. 6. …

… of molecularly targeted therapies in GC and GEJ cancer. … nominated potential targets for
novel therapies and biomarkers for … developments of molecularly targeted therapies in GEJ/GC. …

… Here we will review the major clinical trials testing EGFR-targeted therapies in GE-Ca.
Biomarkers relevant to other cancer types do not appear to be relevant in GE-Ca, and the majority …

… We demonstrated clinical benefit with anti-EGFR targeted therapy in clinical scenarios that
historically have poor response rates to conventional therapies. In particular, three patients …

… response to HER2-targeted therapy such as trastuzumab or … gastroesophageal cancer that
include targeted therapy and … , incurable, metastatic gastroesophageal AC or SCC whose …

… 1% gastroesophageal adenocarcinoma, … targeted therapy in gastric cancer is promising.
Numerous clinical trials evaluating the combination immune therapy with molecularly targeted …

… targeted therapies have emerged along with novel strategies in combining targeted therapies
… the use of targeted therapies in the treatment of gastroesophageal cancer and touch upon …

… adenocarcinoma of the gastroesophageal junction remains poor. Over the years, new targeting
… studies testing targeted therapies in GEJA by separately analyzing targeted oncogenic …

… However, development of targeted therapies for gastroesophageal … , targeted therapy and
esophageal adenocarcinoma and targeted therapy and gastroesophageal adenocarcinoma. …

… In this review, we expound an outline of the latest advances in targeted therapies of
esophageal cancer and the mechanisms of relevant drugs, discuss their efficacy and safety, and …